Life Sciences and Biotechnology Stock On Investment News Show

Biotech stocks to buy

June 16, 2015 Investment News Show featured a live interview with

Enzo Biochem Inc. (ENZ)

Director and President, BARRY W. WEINER 

Hear Part 1 of the show:


Watch Part 1 Video

small cap biotech stocks to buy


Hear Part 2 of the Show with Barry Weiner of Enzo Biochem Inc. interview:


Watch Part 2 Video

Undervalued biotech stocks

biotechnology stock to buy

Visit ENZO Corporate Site

Get ENZ stock quote, trading charts, and latest news – Click Here

undervalued biotechnology stock to buy

Enzo Biochem is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and provides reference laboratory services to the medical community.

biotech stock to buy

Founded in 1976, we have concentrated on the development of enabling technologies in the areas of gene regulation and gene modification. Many of our technologies are applicable to the biomedical and pharmaceutical research markets, and we are further using these technologies as a platform for our entry into the clinical diagnostics market.

biotech stock news

Today, Enzo technologies and products are recognized as the key tools in non-radioactive gene labeling used by researchers worldwide. Additionally, Enzo’s work in gene analysis has led to development of a number of significant therapeutic candidates for the treatment of viral and immunological based disorders, several of which are in various phases of human clinical trials.

medical stock to buy

In the course of our extensive research and development activities, we have built a significant patent position consisting of numerous pioneer patents and applications that encompass our core technologies.

The business activities of Enzo Biochem are performed by the company’s three wholly owned subsidiaries:

Enzo Life Sciences, Enzo Therapeutics and Enzo Clinical Labs.

Such activities include research and development, manufacturing and marketing of biomedical research products and tools through Enzo Life Sciences and research and development of therapeutic products through Enzo Therapeutics and the operation of a regional clinical reference laboratory through Enzo Clinical Labs.

Enzo’s vision of the importance of recombinant DNA technology as an informational source more than two decades ago has now become a major direction in modern medicine.

See Enzo Stock News — Click Here

Enzo Biochem Reports Third Quarter Results, Including Strong Revenue Growth at Clinical Labs Reflecting Increasing Volume and Greater Molecular Diagnostic Activity — See More


BARRY W. WEINER, President, Chief Financial Officer, Principal Accounting Officer and Director and a founder of Enzo Biochem. He has served as the Company’s President since 1996, and previously held the position of Executive Vice President. Before his employment with Enzo Biochem, he worked in several managerial and marketing positions at the Colgate Palmolive Company. Mr. Weiner is a member of the New York Biotechnology Association. He received his Bachelor of Arts degree in Economics from New York University and a Master of Business Administration in Finance from Boston University.

Life Sciences and Biotechnology Stock